ストックスクリーナーアプリを入手
0.353
3.29%
-0.012
アフターアワーズ：
.36
0.007
+1.98%
前日終値:
$0.365
開ける：
$0.366
24時間の取引高:
227.72K
Relative Volume:
0.44
時価総額：
$3.21M
収益：
-
当期純損益:
$-15.08M
株価収益率:
-0.0302
EPS:
-11.7
ネットキャッシュフロー:
$-11.56M
1週間 パフォーマンス:
-26.06%
1か月 パフォーマンス:
-21.05%
6か月 パフォーマンス:
-57.98%
1年 パフォーマンス:
-76.47%
1日の値動き範囲:
$0.3323
$0.3701
1週間の範囲:
$0.3323
$0.52
52週間の値動き範囲:
$0.3323
$2.92
Enveric Biosciences Inc Stock (ENVB) Company Profile
名前
Enveric Biosciences Inc
セクター
電話
239-302-1707
住所
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
ENVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ENVB | 0.353 | 3.21M | 0 | -15.08M | -11.56M | -11.70 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Enveric Biosciences Inc (ENVB) 最新ニュース
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders - Benzinga
atai Life Sciences and Enveric Biosciences Report Q3 2024 Results - Microdose Psychedelic Insights
Enveric Biosciences narrows net loss, advances lead drug candidate - Green Market Report
Enveric Biosciences Inc (ENVB) Quarterly 10-Q Report - Quartzy
Enveric Biosciences Narrows Q3 Loss, Advances Mental Health Drug Development | ENVB Stock News - StockTitan
Enveric Biosciences licenses drug candidate to MycoMedica By Investing.com - Investing.com Australia
Enveric and MycoMedica’s New Licensing Agreement Marks a Strategic Shift in Mental Health Treatment - Microdose Psychedelic Insights
Enveric Biosciences licenses drug candidate to MycoMedica - Investing.com India
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 - BioSpace
Enveric inks $62M licensing deal for psilocin prodrug - Green Market Report
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal - Benzinga
Enveric Strikes $62M Licensing Deal with MycoMedica for Mental Health Drug Pipeline | ENVB Stock News - StockTitan
Enveric Biosciences (NASDAQ:ENVB) Trading 1.1% Higher – Time to Buy? - Defense World
Enveric Biosciences Expands Patent Portfolio - Microdose Psychedelic Insights
Enveric Biosciences secures new US patents for drug library By Investing.com - Investing.com Canada
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions - MSN
Enveric Biosciences Announces Broad Range of Patent Issuances - The Bakersfield Californian
Psychedelic Drugs Market exhibit a CAGR of 13.9% for the forecast - openPR
Financial Metrics Check: Enveric Biosciences Inc (ENVB)’s Ratios for Trailing Twelve Months - The Dwinnex
ENVB stock touches 52-week low at $0.4 amid market fluctuations - Investing.com
Enveric Biosciences Inc (ENVB) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Enveric Biosciences Unveils Positive Safety and Pharmacology Data for EB-003 - Microdose Psychedelic Insights
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 - Business Wire
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop - Business Wire
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit - BioSpace
A Tale of Resilience: Enveric Biosciences Inc Amid Stock Market Turbulence - The InvestChronicle
What to expect from Enveric Biosciences Inc’s (ENVB) current quarter earnings? - US Post News
SEC Form 424B4 filed by Enveric Biosciences Inc. - Quantisnow
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Enveric Biosciences Announces Upcoming Investor Presentation Release - TipRanks
Enveric Biosciences Inc (ENVB) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Enveric secures patent for radiation dermatitis topical product By Investing.com - Investing.com Australia
Enveric secures patent for radiation dermatitis topical product - Investing.com
Enveric Biosciences narrows second-quarter loss, pushes non-hallucinogenic pipeline - Green Market Report
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions - StockTitan
Enveric Biosciences, Inc. (NASDAQ:ENVB) Sees Significant Increase in Short Interest - Defense World
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024 - InvestorPlace
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results - StockTitan
33,835 Shares in Enveric Biosciences, Inc. (NASDAQ:ENVB) Bought by Virtu Financial LLC - Defense World
What was Enveric Biosciences Inc (ENVB)’s performance in the last session? - US Post News
Contrasting Enveric Biosciences (NASDAQ:ENVB) and Prestige Consumer Healthcare (NYSE:PBH) - Defense World
Financial Analysis: Cocrystal Pharma (NASDAQ:COCP) & Enveric Biosciences (NASDAQ:ENVB) - Defense World
Enveric Biosciences (NASDAQ:ENVB) Stock Price Up 8% - Defense World
Ratio Revelations: Enveric Biosciences Inc (ENVB)’s Financial Metrics in the Spotlight - The Dwinnex
You might want to take a look at Enveric Biosciences Inc (ENVB) now - SETE News
ENVB Stock: Exploring Enveric Biosciences Inc’s Growth - The InvestChronicle
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today? - InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - InvestorPlace
Enveric Biosciences Announces Promising Preclinical Results for EB-003 - Microdose Psychedelic Insights
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally - StockTitan
Check Out Enveric Biosciences Inc (ENVB)’s Trade Data Rather Than the Analysts’ Views - SETE News
Enveric Biosciences Inc (ENVB) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):